IL155194A0 - Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same - Google Patents

Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Info

Publication number
IL155194A0
IL155194A0 IL15519401A IL15519401A IL155194A0 IL 155194 A0 IL155194 A0 IL 155194A0 IL 15519401 A IL15519401 A IL 15519401A IL 15519401 A IL15519401 A IL 15519401A IL 155194 A0 IL155194 A0 IL 155194A0
Authority
IL
Israel
Prior art keywords
pravastatin
epi
substantially free
compositions containing
lactone
Prior art date
Application number
IL15519401A
Other languages
English (en)
Original Assignee
Biogal Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22897222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL155194(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogal Pharmaceutical Co Ltd filed Critical Biogal Pharmaceutical Co Ltd
Publication of IL155194A0 publication Critical patent/IL155194A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15519401A 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same IL155194A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23827800P 2000-10-05 2000-10-05
PCT/US2001/031230 WO2002030415A1 (en) 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Publications (1)

Publication Number Publication Date
IL155194A0 true IL155194A0 (en) 2003-11-23

Family

ID=22897222

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15519401A IL155194A0 (en) 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Country Status (18)

Country Link
EP (1) EP1330245A4 (enExample)
JP (6) JP3737801B2 (enExample)
KR (1) KR20030059173A (enExample)
CN (1) CN1468098A (enExample)
AU (1) AU2002211462A1 (enExample)
CA (1) CA2422744A1 (enExample)
CZ (1) CZ20031166A3 (enExample)
HR (1) HRP20030347A2 (enExample)
HU (1) HUP0400913A2 (enExample)
IL (1) IL155194A0 (enExample)
IS (1) IS6766A (enExample)
MX (1) MXPA03002963A (enExample)
NO (1) NO20031532L (enExample)
NZ (1) NZ525631A (enExample)
PL (1) PL361230A1 (enExample)
SK (1) SK5232003A3 (enExample)
WO (1) WO2002030415A1 (enExample)
ZA (1) ZA200302313B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1798214A3 (en) * 1999-11-30 2007-08-01 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for recovering statin compounds from a fermentation broth
SI1265604T1 (sl) * 1999-11-30 2007-04-30 Sag Teva Gyogyszergyar Zartkoe Postopek za ponovno pridobivanje statinskih spojin iz fermentacije brozge
YU39102A (sh) * 1999-11-30 2006-01-16 Biogal Gyogyszergyar Rt Postupak dobijanja statina iz fermentacione smeše
JP2003516959A (ja) 1999-12-14 2003-05-20 ビオガル ジョジセルジャール アール テー． プラバスタチンナトリウムの新規フォーム
JP3737801B2 (ja) * 2000-10-05 2006-01-25 テバ ジョジセルジャール レースベニュタールシャシャーグ プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1452519A1 (en) * 2003-02-25 2004-09-01 Balkanpharma-Razgrad AD Method for the isolation and purification of pravastatin sodium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
ATE412409T1 (de) * 2003-11-24 2008-11-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur reinigung von pravastatin
NZ552389A (en) 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
ES2254028B1 (es) * 2004-11-29 2007-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de pravastatina sodica purificada.
US20070004737A1 (en) * 2005-02-25 2007-01-04 Inbal Ornan Process of purifying tadalafil
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN114031496B (zh) * 2021-11-30 2024-09-27 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378441A (en) * 1963-10-17 1968-04-16 S B Penick & Company Tetraene antibiotic purification
JPS5221594B2 (enExample) * 1973-09-29 1977-06-11
YU40452B (en) * 1975-02-07 1986-02-28 Beecham Group Plc Process for the elimination of contaminating impurities from clavulinic acid
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
JPS5890509A (ja) * 1981-11-25 1983-05-30 Sankyo Co Ltd 高コレステロ−ル血症治療用組成物
JPH01190661A (ja) * 1988-01-22 1989-07-31 Konishi Kagaku Kogyo Kk ４，４′−ジヒドロキシジフエニルスルホンの精製法
JP2739328B2 (ja) * 1988-09-14 1998-04-15 日本ケミファ株式会社 ベンズイミダゾール化合物の精製方法
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
JPH06256278A (ja) * 1993-03-03 1994-09-13 Nissan Chem Ind Ltd 光学活性α−カルバモイルアルカン酸誘導体およびその製法
CA2126365C (en) * 1993-07-06 1999-08-24 Steven W. Felman Recovery of citric acid from impure process streams by addition of strong acids and salts thereof
WO1995027073A1 (en) * 1994-03-31 1995-10-12 Pfizer Inc. Process for natamycin recovery
PT784605E (pt) * 1995-08-03 2000-08-31 Dsm Nv Processo selectivo para a desacilacao de compostos acetilados campo e antecedentes da invencao
JPH09124655A (ja) * 1995-11-01 1997-05-13 Sankyo Co Ltd 新規スクアレンシンターゼ阻害活性化合物
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
JP2000229855A (ja) * 1998-12-07 2000-08-22 Satoshi Takebe プラバスタチンナトリウム錠
BR0009180A (pt) * 1999-02-03 2002-03-26 Inst Drug Res Ltd Processo microbiológico para a preparação de pravastatin
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
YU39102A (sh) * 1999-11-30 2006-01-16 Biogal Gyogyszergyar Rt Postupak dobijanja statina iz fermentacione smeše
JP3737801B2 (ja) * 2000-10-05 2006-01-25 テバ ジョジセルジャール レースベニュタールシャシャーグ プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物

Also Published As

Publication number Publication date
EP1330245A1 (en) 2003-07-30
AU2002211462A1 (en) 2002-04-22
NO20031532D0 (no) 2003-04-04
NZ525631A (en) 2005-05-27
HRP20030347A2 (en) 2005-04-30
WO2002030415A9 (en) 2002-10-31
SK5232003A3 (en) 2004-06-08
CZ20031166A3 (cs) 2004-04-14
EP1330245A4 (en) 2004-10-20
NO20031532L (no) 2003-04-04
JP2009268479A (ja) 2009-11-19
IS6766A (is) 2003-04-01
ZA200302313B (en) 2004-03-25
JP2006036781A (ja) 2006-02-09
JP3737801B2 (ja) 2006-01-25
KR20030059173A (ko) 2003-07-07
JP2004510817A (ja) 2004-04-08
CA2422744A1 (en) 2002-04-18
JP2015212300A (ja) 2015-11-26
MXPA03002963A (es) 2005-01-25
JP2013128486A (ja) 2013-07-04
CN1468098A (zh) 2004-01-14
PL361230A1 (en) 2004-10-04
WO2002030415A1 (en) 2002-04-18
HUP0400913A2 (en) 2006-11-28
JP2005013238A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
HRP20030347A2 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
AU3459702A (en) Branched primary alcohol compositions and derivatives thereof
HUP0302297A3 (en) Substituted thioacetamides and pharmaceutical compositions containing them
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
IL137363A (en) Pharmaceutical compositions containing mupirocin
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
GB2368014B (en) Pharmaceutical composition containing citalopram
IL154068A0 (en) Highly purified simvastatin compositions
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
IL150187A0 (en) Novel forms of pravastatin sodium
GB0029847D0 (en) Preparation of spheroids
IL151715A0 (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
AU9482601A (en) Tocol-based compositions containing amiodarone
IL159614A0 (en) Benzofuran derivatives and pharmaceutical compositions containing the same
HUP0302531A3 (en) Pharmaceutical compositions containing citalopram
HK1055685A (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
AU2001272490A1 (en) Use of galiella lactone
AU2001264324A1 (en) Method of stabilizing medicinal compositions containing pravastatin
AU2001294374A1 (en) 2-acylindenes and these containing perfume compositions
AU7057701A (en) New use as antihelmintics of albofungin and analogs
GB0000916D0 (en) New compositions of matter
ZA200204500B (en) Forms of pravastatin sodium.
AU2002216388A1 (en) Benzofuran derivatives and pharmaceutical compositions containing the same
PL340617A1 (en) Derivatives of 2-acylpyridine
TW468475U (en) Structure of gravity-suction-type perfume